DAWNRAYS PHARMA

Founded in 1995/12, Dongrui Pharmaceutical is mainly engaged in the development, manufacture and sale of cephalosporin antibiotics and systemic specialty drugs. Dongrui Pharmaceutical (Holdings) Limited was listed on the main board of the Hong Kong Stock Exchange on July 11, 2003, stock code: 2348. Dongrui Pharmaceutical (Holdings) Co., Ltd. has nine subsidiaries including Dongrui International Co., Ltd., Dongrui International Co., Ltd., Dongrui Biotech Investment and Development (Asia) Co., Ltd., Suzhou Dongrui Pharmaceutical Technology Co., Ltd., Dongrui (Nantong) Pharmaceutical Technology Co., Ltd., Dongrui Pharmaceutical (Hong Kong) Co., Ltd., Fujian Dongrui Pharmaceutical Co., Ltd., and Lanzhou Dongrui Pharmaceutical Co., Ltd. As a Hong Kong listed company, the Group's overall decision-making and management strictly abides by Hong Kong's corporate governance requirements. Its business positioning is global, has a global perspective and is inclusive of world culture, and is an enterprise that investors can trust. Dongrui Pharmaceutical's cephalosporin antibiotic products include intermediates, raw anthers, and powder injections; specialty drugs cover the cardiovascular system, anti-hepatitis B virus, anti-allergy, digestive system, urinary system, and endocrine system. The dosage forms include tablets, capsules, and granules. In terms of cephalosporin antibiotic production, Dongrui Pharmaceutical has developed comprehensive production characteristics from pharmaceutical intermediates and raw anthers to formulations. In particular, it has an advanced technology platform for third-generation cephalosporin synthesis, product quality has reached international advanced levels, and has built a cephalosporin industry chain with a complete range of varieties, perfect comprehensive supporting functions, and high production potential. It is the preferred raw material supplier for major domestic pharmaceutical manufacturers and many foreign pharmaceutical manufacturers. The Dongrui Pharmaceutical R&D Center was established in 2002 with nearly 50 core R&D personnel. It is an R&D team composed of senior researchers such as PhDs and masters, with professional and technical personnel as the backbone. The research direction is mainly based on synthetic anthers for systemic specialty drugs. At the same time, it also takes into account the development of three types of new anthers and the exploration of some innovative anthers. The annual R&D investment accounts for about 10% of the sales amount of system specialty drugs. At present, Dongrui Pharmaceutical has established the “An” series of cardiovascular drug brands, and the group's specialty drugs, amlodipine benzenesulfonate tablets (annezin), losartan potassium hydrochlorothiazide tablets (Anneki), cetirizine hydrochloride tablets (cicobil), and entecavir dispersible tablets (Raytec) are among the first batch of products approved for production and marketing in China, with the highest market share. Dongrui Pharmaceutical has formed 4 sales teams according to different product lines, covering hospitals, distribution, raw materials, and import and export models. Currently, there are around 550 sales staff and more than 90 offices across the country, of which 40% are in first-tier cities and 30% are in second-tier cities. Therefore, Dongrui Pharmaceutical has a good ability to quickly cover new products to hospitals. Dongrui Pharmaceutical has a complete quality management system, and the existing plant is built in strict accordance with EU standards. Dongrui Pharmaceutical will always be committed to the cause of human health. With a high sense of social responsibility and forward-looking thinking, Dongrui Pharmaceutical will continue to provide safe and effective medicines to society through continuous technological innovation, become a world-class pharmaceutical company, and make the ultimate contribution to the cause of human health.